康缘药业：上半年净利润1.42亿元，同比下降40.12%

Summary of Key Points Core Viewpoint - Kangyuan Pharmaceutical (600557) reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its business performance [1]. Financial Performance - The company achieved an operating revenue of 1.642 billion yuan, representing a year-on-year decrease of 27.29% [1]. - The net profit attributable to shareholders was 142 million yuan, down 40.12% compared to the previous year [1]. - The basic earnings per share stood at 0.25 yuan [1].